摘要
目的探究和分析氨曲南在肿瘤患者下呼吸道感染治疗中的应用效果。方法选取该院在2019年3—10月期间收治的肿瘤患者合并下呼吸道感染的患者总计84例,按照随机数表法分为研究组和对照组,各42例。研究组的患者采用氨曲南进行治疗,对照组的患者采取常规抗菌药物头孢他啶进行治疗,治疗疗程为1~2周,比较两组患者的临床治疗有效率,不良反应的发生率以及患者感染控制的时间。结果研究组患者的临床治疗有效率为92.3%,对照组为81.0%,研究组明显高于对照组,差异有统计学意义(χ^(2)=4.935,P<0.05),研究组的不良反应发生率为9.5%,对照组为14.3%,研究组的发生率明显低于对照组,差异有统计学意义(χ^(2)=5.281,P<0.05),研究组的患者感染控制的时间为(5.7±1.3)d,对照组为(7.9±1.7)d,研究组明显短于对照组,差异有统计学意义(t=11.294,P<0.05)。结论氨曲南药物应用于肿瘤患者的下呼吸道感染的治疗中有较好的杀菌效果,能够缩短治疗的疗程,有效地改善患者的下呼吸道感染情况,并且不良反应的发生率较低,临床治疗效果值得肯定。
Objective To explore and analyze the effect of aztreonam in the treatment of lower respiratory tract infections in cancer patients.Methods A total of 84 tumor patients with lower respiratory tract infections admitted to the hospital from March to October 2019 were selected and divided into study group and control group according to the random number table method,with 42 cases in each group.Patients in the study group were treated with aztreonam,and patients in the control group were treated with the conventional antibacterial drug ceftazidime.The treatment course was 1-2 weeks.The clinical treatment efficiency,incidence of adverse reactions and infection control of the two groups were compared.Results The clinical treatment effective rate of the study group was 92.3%,and the control group was 81.0%.The study group was significantly higher than the control group,and the difference was statistically significant(χ^(2)=4.935,P<0.05).The adverse reaction rate of the study group was 9.5%,the control group was 14.3%.The incidence of the study group was significantly lower than that of the control group,and the difference was statistically significant(χ^(2)=5.281,P<0.05).The time for infection control in the study group was(5.7±1.3)d,and the control group was(7.9±1.7)d.The study group was significantly shorter than the control group,the difference was statistically significant(t=11.294,P<0.05).Conclusion The application of aztreonam in the treatment of lower respiratory tract infections in cancer patients has a good bactericidal effect,can shorten the treatment course,effectively improve the patients'lower respiratory tract infections,and the incidence of adverse reactions is low,clinical treatment effect is worthy of recognition.
作者
徐东
XU Dong(Department of Internal Medicine,Wucheng County People's Hospital,Dezhou,Shandong Province,253300 China)
出处
《系统医学》
2021年第2期71-73,共3页
Systems Medicine
关键词
氨曲南
肿瘤
下呼吸道感染
应用效果
Aztreonam
Tumor
Lower respiratory tract infection
Application effect
